Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 10/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 10/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.32 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2018538 | 0.83 | SYK (0.38) | CYP19A1SMN1; SMN2GABRA1GABRG2GABRB3 | |
| SCHEMBL1661164 | 0.81 | GABRA1 (0.39) | CYP19A1GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL31543495 | 0.81 | GABRA1 (0.39) | CYP19A1GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL30632766 | 0.79 | GABRA1 (0.38) | CYP19A1GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL26686630 | 0.79 | GABRA1 (0.38) | CYP19A1GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL20015961 | 0.79 | GABRA1 (0.32) | CYP19A1GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL31009000 | 0.79 | NUDT1 (0.34) | CYP19A1GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL22576011 | 0.79 | NUDT1 (0.34) | CYP19A1GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL2505184 | 0.78 | SYK (0.35) | CYP19A1CYP3A4TSHRCYP2C19SYK | |
| SCHEMBL17059648 | 0.77 | FFAR1 (0.35) | SMN1; SMN2CYP3A4CYP2C19MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025233837-A1 | 4H-PYRIMIDO[1,2-A]PYRIMIDIN-4-ONE DERIVATIVES FOR USE AS NLRP3 INFLAMMASOME INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDER | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-11-13 | — | — | WO | disclosed |
| US-20250304577-A1 | TYK2 INHIBITORS | BIOGEN MA INC. | 2025-10-02 | — | — | US | disclosed |
| CN-119654322-A | TYK2 inhibitors | 渤健马萨诸塞州股份有限公司 | 2025-03-18 | — | — | CN | disclosed |
| US-20240317725-A1 | LPA1 SMALL MOLECULE ANTAGONIST | TUOJIE BIOTECH (SHANGHAI) CO., LTD. (CN) | 2024-09-26 | — | — | US | disclosed |
| EP-4375277-A1 | LPA1 SMALL MOLECULE ANTAGONIST | Tuojie Biotech (Shanghai) Co., Ltd. (CN) | 2024-05-29 | — | — | EP | disclosed |
| CN-117460721-A | LPA1 small molecule antagonist | 上海拓界生物医药科技有限公司 | 2024-01-26 | — | — | CN | disclosed |
| US-20230339936-A1 | COMPOUND HAVING KINASE INHIBITORY ACTIVITY | CYTOSINLAB THERAPEUTICS CO., LTD. (CN) | 2023-10-26 | — | — | US | disclosed |
| EP-4186901-A1 | COMPOUND HAVING KINASE INHIBITORY ACTIVITY | Cytosinlab Therapeutics Co., Ltd. (CN) | 2023-05-31 | — | — | EP | disclosed |
| WO-2023001177-A1 | LPA1 SMALL MOLECULE ANTAGONIST | 上海拓界生物医药科技有限公司 | 2023-01-26 | — | — | WO | disclosed |
| WO-2023001177-A1 | LPA1 SMALL MOLECULE ANTAGONIST | 上海拓界生物医药科技有限公司 | 2023-01-26 | — | — | WO | disclosed |
| CN-102858767-A | Aminopyrimidines as SYK inhibitors | MERCK SHARP & DOHME | 2013-01-02 | — | — | CN | disclosed |
| US-20120277192-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME LLC | 2012-11-01 | — | — | US | disclosed |
| EP-2515657-A1 | TYROSINE KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-10-31 | — | — | EP | disclosed |
| EP-2513098-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-10-24 | — | — | EP | disclosed |
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-10-18 | — | — | US | disclosed |
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-10-18 | — | — | US | disclosed |
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-10-18 | — | — | US | disclosed |
| US-20110245205-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME LLC | 2011-10-06 | — | — | US | disclosed |
| WO-2011084402-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-07-14 | — | — | WO | disclosed |
| WO-2011075515-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | ABL1, MET, ERBB2 | CYP19A1 3861/4885SMN1; SMN2 3605/4885L3MBTL1 1158/4885 |
| US-20110245205-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | SYK, BTK, LCK | CYP19A1 1405/4885SMN1; SMN2 4226/4885L3MBTL1 4452/4885 |
| US-20250304577-A1 | TYK2 INHIBITORS | TYK2, JAK2, JAK1 | CYP19A1 2585/4885SMN1; SMN2 1067/4885L3MBTL1 2886/4885 |
| US-20230339936-A1 | COMPOUND HAVING KINASE INHIBITORY ACTIVITY | FLT3, ERBB2, ABL1 | CYP19A1 1306/4885SMN1; SMN2 4360/4885L3MBTL1 2941/4885 |
| US-20240317725-A1 | LPA1 SMALL MOLECULE ANTAGONIST | LPAR1, LPAR2, LPAR4 | CYP19A1 1518/4885SMN1; SMN2 3596/4885L3MBTL1 3038/4885 |
| US-20120277192-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | SYK, BTK, LCK | CYP19A1 1405/4885SMN1; SMN2 4226/4885L3MBTL1 4452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.